What Are the Warning Signs of PML in Tysabri Patients?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Occupational Risk Awareness

If you or a loved one is taking Tysabri and experiencing new neurological symptoms, understanding the warning signs of progressive multifocal leukoencephalopathy (PML) is critical. The long-standing tradition of medical risk communication has always emphasized balancing therapeutic benefit with potential harm, and this page continues that legacy by focusing on the specific PML risk factors and symptoms associated with Tysabri. Here, we provide a clear, factual overview of what to watch for and how PML is monitored.

Understanding Tysabri and Its Link to Progressive Multifocal Leukoencephalopathy

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for moderate-to-severe active Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The United States Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning underscores the gravity of the adverse event and the need for careful patient selection and monitoring. The clinical presentation of PML is variable but typically includes progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis relies on brain imaging, typically magnetic resonance imaging showing characteristic white matter lesions, and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction. The disease often progresses rapidly, leading to severe disability or death.

Risk Factors and Mechanism of PML Development

The FDA-approved labeling for Tysabri identifies three primary risk factors for PML: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy, balancing expected benefit against PML risk. The mechanistic pathway linking Tysabri to PML involves the drug's mode of action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammatory activity in conditions like multiple sclerosis but also impairs normal immune surveillance in the brain. The JC virus, which is latent in many individuals, can reactivate and cause PML when immune control is compromised. By blocking lymphocyte trafficking, Tysabri creates an environment permissive for JC virus replication and neural cell infection, leading to PML.

Adequacy of Warnings and Regulatory Measures

Regarding the adequacy of warnings, the FDA has mandated a boxed warning and a restricted distribution program called the TOUCH Prescribing Program. Under this program, patients must read a Medication Guide, understand the risks, and sign an enrollment form; pharmacies and infusion centers must be certified to dispense or infuse Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, PML cases continue to occur, raising questions about whether the warnings are sufficient to prevent harm or to inform patients fully of the risks.

Statute of Limitations for Tysabri Claims in Virginia

For patients affected by Tysabri-associated PML, attorney-related considerations are important. In Virginia, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or reasonably should have been discovered. This timeline is critical because PML symptoms may develop insidiously, and the connection to Tysabri may not be immediately apparent. The latency period between Tysabri exposure and PML onset can range from months to years, often exceeding two years of treatment. Patients or their families should consult with a legal professional promptly to assess whether their claim falls within the statutory window. Evidence of harm, such as medical records documenting PML diagnosis and Tysabri use, will be essential. The timeline between exposure and documented harm is a key factor in both medical management and legal action. PML risk increases with longer Tysabri treatment, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Once PML develops, the disease can progress rapidly, leading to irreversible neurological damage. Early detection and discontinuation of Tysabri may improve outcomes, but many patients still suffer severe disability. For legal purposes, the date of diagnosis or the date when symptoms first appeared and were linked to Tysabri may trigger the statute of limitations. Given the complexity of PML diagnosis and the potential for delayed recognition, affected individuals should seek both medical and legal advice without delay.

Conclusion and Next Steps

In summary, Tysabri carries a known risk of PML, a devastating brain infection. The FDA has implemented warnings and a restricted distribution program, but cases continue to occur. Patients in Virginia who develop PML after Tysabri use should be aware of the two-year statute of limitations for personal injury claims and the importance of timely legal consultation. The evidence supports that PML risk is influenced by anti-JCV antibody status, treatment duration, and prior immunosuppressant use, and that the drug's mechanism of action facilitates JC virus reactivation in the brain. References https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Virginia?

In Virginia, the statute of limitations for personal injury claims, including those related to Tysabri-associated PML, is generally two years from the date the injury was discovered or reasonably should have been discovered. It is crucial to consult with an attorney promptly to ensure your claim is filed within this window.

What are the primary risk factors for developing PML while on Tysabri?

The FDA has identified three primary risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressant medications. These factors should be carefully considered when initiating and continuing Tysabri therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Tysabri Labeling

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.